These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24319080)

  • 1. Dabigatran Use in the Real World: A Multihospital System Experience.
    Kimmons LA; Kabra R; Davis M; Segars BV; Oliphant CS
    J Pharm Pract; 2014 Aug; 27(4):384-8. PubMed ID: 24319080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
    Blair HA; Keating GM
    Drugs; 2017 Mar; 77(3):331-344. PubMed ID: 28185082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R; Smith RE; Henry BL
    J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
    Scott KA; Amirehsani KA
    J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
    J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients.
    Koike H; Fujino T; Koike M; Yao S; Akitsu K; Shinohara M; Yuzawa H; Suzuki T; Ikeda T
    Future Cardiol; 2018 Jan; 14(1):27-36. PubMed ID: 29199852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
    Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review.
    Milling TJ; Fromm C; Ganetsky M; Pallin DJ; Cong J; Singer AJ
    Ann Emerg Med; 2017 May; 69(5):531-540. PubMed ID: 28196608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
    Russo V; Bianchi V; Cavallaro C; Vecchione F; De Vivo S; Santangelo L; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.